高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2026年8月17日 星期一

偏鄉民眾很喜歡打止痛針 ketorolac

2026-08-18 11:14AM






下面這篇是台大的研究. 使用健保資料庫研究口服或注射 NSAID 非類固醇消炎止痛藥. 與新發生急性心肌梗塞住院患者的關聯性. 

使用NSAID的民眾. 共 1370萬人.  8354 例新發生急性心肌梗塞
口服NSAID發生AMI風險 1.42 
注射NSAID發生AMI風險 3.35
Ketorolac 發生AMI風險高於其他NSAID 
口服Ketorolac 發生AMI風險 2.02
注射Ketorolac 發生AMI風險 4.27
其他口服NSAID也會增加AMI風險. 包含下面5種. 
flurbiprofen, ibuprofen, sulindac, diclofenac, and parenteral ketoprofen 



背景
先前研究已證實,某些非類固醇抗發炎藥(NSAIDs)的使用會增加心血管風險。儘管如此,許多老牌NSAIDs仍在全球廣泛使用。迄今為止,大多數研究集中於特定的口服藥物,或受限於病例數。我們針對全國人群,研究了目前使用多種口服和注射用NSAIDs與新發急性心肌梗塞(AMI)住院風險之間的關係,並將研究結果與現有證據進行了比較。

方法
我們利用台灣全民健康保險資料庫進行了一項病例交叉研究,納入了2006年因新發急性心肌梗塞(AMI)住院的患者。對於每位患者,入院前1-30天和91-120天分別被定義為病例期和匹配對照期。採用條件logistic迴歸分析比較了各時期非類固醇抗發炎藥(NSAIDs)的使用情況,並校正了合併用藥的影響。

結果
共有8354例新發急性心肌梗塞(AMI)住院患者符合研究標準。根據1,370萬非類固醇抗發炎藥(NSAIDs)使用者的用藥情況,篩選出14種口服NSAIDs和3種注射用NSAIDs。

調整後的比值比(aOR)(95%信賴區間)顯示,口服和注射用非選擇性NSAIDs與AMI風險的關聯性分別為1.42(1.29,1.56)和3.35(2.50,4.47),且注射用藥物的關聯性顯著高於口服藥物(pp<0.01)。在所研究的口服和注射用NSAIDs中,酮咯酸與AMI風險的關聯性最高,其aOR分別為2.02(1.00,4.09)和4.27(2.90,6.29)。口服氟比洛芬、布洛芬、舒林酸、雙氯芬酸以及注射酮洛芬均與急性心肌梗塞風險顯著增加有關。本研究結果與先前研究的大多數證據一致。

結論
綜合證據表明,目前使用某些非類固醇抗發炎藥物(NSAIDs)會增加急性心肌梗塞(AMI)的風險。本研究觀察到,使用注射用NSAIDs與較高的AMI風險有關。在所研究的口服和注射NSAIDs中,酮咯酸的風險最高。儘管需要進一步研究來證實這種關聯,但處方醫生和公眾在使用NSAIDs時應謹慎對待AMI的潛在風險。

背景
非類固醇類抗發炎藥(NSAIDs)是常用的消炎止痛藥。由於大量人口暴露於NSAIDs,服用NSAIDs的患者發生嚴重心血管不良反應的風險已成為臨床和公共衛生領域的關注焦點[ 近期探討心血管風險與NSAIDs使用之間關聯的研究,包括隨機對照試驗和觀察性研究,大多集中於環氧合酶-2選擇性抑制劑(COX-2抑制劑)cyclooxygenase-2 selective inhibitors (COX-2) 某些非選擇性NSAIDs(ns-NSAIDs),且受限於病例數 1-32 AMI)的風險。本研究的目的是評估在門診診所環境中使用各種口服和腸外非類固醇抗發炎藥物導致急性心肌梗塞住院的風險,並將結果與現有證據進行比較。

Abstract

Background

Previous studies have documented the increased cardiovascular risk associated with the use of some nonsteroidal anti-inflammatory drugs (NSAIDs). Despite this, many old NSAIDs are still prescribed worldwide. Most of the studies to date have been focused on specific oral drugs or limited by the number of cases examined. We studied the risk of new acute myocardial infarction (AMI) hospitalization with current use of a variety of oral and parenteral NSAIDs in a nationwide population, and compared our results with existing evidence.

Methods

We conducted a case-crossover study using the Taiwan's National Health Insurance claim database, identifying patients with new AMI hospitalized in 2006. The 1-30 days and 91-120 days prior to the admission were defined as case and matched control period for each patient, respectively. Uses of NSAIDs during the respective periods were compared using conditional logistic regression and adjusted for use of co-medications.

Results

8354 new AMI hospitalization patients fulfilled the study criteria. 14 oral and 3 parenteral NSAIDs were selected based on drug utilization profile among 13.7 million NSAID users. The adjusted odds ratio, aOR (95% confidence interval), for risk of AMI and use of oral and parenteral non-selective NSAIDs were 1.42 (1.29, 1.56) and 3.35 (2.50, 4.47), respectively, and significantly greater for parenteral than oral drugs (p for interaction < 0.01). Ketorolac was associated with the highest AMI risk among both of oral and parenteral NSAIDs studied, the aORs were 2.02 (1.00, 4.09) and 4.27 (2.90, 6.29) respectively. Use of oral flurbiprofen, ibuprofen, sulindac, diclofenac, and parenteral ketoprofen were also significantly associated with increased AMI risk. The results of the present study were consistent with the majority of evidence from previous studies.

Conclusions

The collective evidence revealed the tendency of increased AMI risk with current use of some NSAIDs. A higher AMI risk associated with use of parenteral NSAIDs was observed in the present study. Ketorolac had the highest associated risk in both oral and parenteral NSAIDs studied. Though further investigation to confirm the association is warranted, prescribing physicians and the general public should be cautious about the potential risk of AMI when using NSAIDs.

Background

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for reducing inflammation and relief pain. Due to large population exposed to NSAIDs, the risk of serious adverse cardiovascular effect for patient taking NSAIDs is an area of concern, from both a clinical and public health perspective [-]. Despite the frequent prescription of a wide variety of old oral and parenteral NSAIDs, recent studies exploring links between cardiovascular risk and NSAIDs use, including randomized controlled trials and observational studies, had mostly focused on cyclooxygenase-2 selective inhibitors (COX-2) or some non-selective NSAIDs (ns-NSAIDs), and were limited by the number of cases examined [-,-]. The assessment of the risk of acute myocardial infarction (AMI) from the use of parenteral NSAIDs was not a focus of the studies. The aim of this study was to assess the risk of hospitalization due to AMI as a result of the use of a variety of oral and parenteral NSAIDs in outpatient-clinic settings, and to compare the results with existing evidence.


筆記-(全聯會)家醫2.0 糖尿病治療新思維-重新定義現代糖尿病照護 DM CKD DKD

 2026-08-18

建議裝連續血糖偵測. 








偏鄉民眾很喜歡打止痛針 ketorolac

2026-08-18 11:14AM ketorolac原廠仿單連結 下面這篇是台大的研究. 使用健保資料庫研究口服或注射 NSAID 非類固醇消炎止痛藥. 與新發生急性心肌梗塞住院患者的關聯性.  使用NSAID的民眾. 共 1370萬人.  8354 例新發生急性心肌梗塞 口...